ABSTRACT
Background Presbycusis, also known as age-related hearing loss (ARHL), is the most frequent sensory disability affecting elderly adults worldwide.ARHL is typified by a bilateral, progressive, sensorineural hearing loss that is pronounced in high frequency. Conventional factors associated with ARHL include diabetes, hypertension, and family history of hereditary hearing loss. The severity of hearing impairment varies between individuals. The accurate causative molecular pathogenesis for ARHL is unknown, therefore the investigation of the underlying pathogenic mechanisms involved in ARHL is imperative for the development of effective therapeutic approaches. Epigenetics is the study of phenotypic changes caused by modification of genetic expression rather than alteration of DNA sequence. It is hypothesized that ARHL could result from unclarified epigenetic susceptibility, nevertheless, there is a shortage of information on the exact contribution of epigenetic modifications to ARHL. Here we present an investigation on the involvement of DNA methylation with Age-related hearing loss.
Results In the present study the Illumina Infinium® Methylation EPIC Beadchip has been used to identify regions with aberrant levels of methylation across genomes from ARHL patients. Hearing measurements were used to determine the audioprofiles. Clinical, audiometric patterns, DNA testing, and methylation pattern screening were undertaken. Our results demonstrate a strong correlation between patients’ hearing measurements and CpG sites methylation in ESPN and TNFRSF25. A Methylation Polymerase chain reaction (PCR) assay was used to confirm methylation levels at specific gene locus in ARHL patients.
Conclusion Aberrant DNA methylation and its impact on gene expression have been implicated in many biological processes. By interrogating methylation status across the genome at single-nucleotide resolution of hearing loss patients, our study can help establish the association between audiometric patterns and methylation status in age-related hearing loss patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Institute of Health. Dr. Liu is supported by NIH grants 321 of R01DC005575, R01DC012115.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Miami institutional review board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Availability of data and material The datasets generated and/or analyzed during the present study are available from the corresponding author on reasonable requests
